Latest Patrys (Asx:Pab) News

Page 1 of 1
Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.
Ada Torres
Ada Torres
26 Nov 2025
Patrys Limited has raised $1.77 million through a fully underwritten entitlement offer to fund preclinical studies and business development for its deoxymab therapeutic antibodies. The company also completed a capital consolidation and held a successful AGM, signaling a strategic pivot into immunology and inflammation.
Ada Torres
Ada Torres
30 Oct 2025
Patrys Limited reported a 14.9% reduction in net loss for FY2025, driven by lower R&D expenses and tax incentives, while impairing key PAT-DX1 assets and shifting focus to PAT-DX3 development.
Ada Torres
Ada Torres
29 Aug 2025
Patrys Limited has completed a modest capital raise and restructured its leadership as it advances its deoxymab antibody program, with a larger entitlement offer announced to fund clinical development and business growth.
Ada Torres
Ada Torres
29 July 2025
Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.
Ada Torres
Ada Torres
23 July 2025
Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.
Ada Torres
Ada Torres
23 July 2025
Patrys Limited has formalized the redundancy of CEO Dr James Campbell, with a $535,877 payout partly converted into shares pending shareholder approval. Dr Campbell will continue as a non-executive director.
Ada Torres
Ada Torres
17 June 2025
Patrys Limited has raised $358,362 through a share placement and announced significant board changes, including the appointment of Dr Anton Uvarov and Mr Peter Christie, alongside making the CEO role redundant.
Ada Torres
Ada Torres
10 June 2025
Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.
Ada Torres
Ada Torres
30 Apr 2025
Patrys Limited has halted plans for a Phase 1 trial of PAT-DX1 following disappointing GMP production results, pivoting its development efforts towards PAT-DX3 and exploring new partnerships.
Ada Torres
Ada Torres
30 Jan 2025